Company Overview - Bid Pharma is located in Yangpu District, Shanghai, and was established on April 27, 2007. The company went public on October 11, 2022. Its main business focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [1]. Business Composition - The revenue composition of Bid Pharma includes: - 43.26% from molecular building block heterocyclic compounds - 23.32% from molecular building block aromatic compounds - 16.36% from molecular building block aliphatic compounds - 10.57% from catalysts and ligands - 6.49% from life science reagents [1]. Market Performance - On September 23, Bid Pharma's stock fell by 5.08%, closing at 70.03 CNY per share, with a trading volume of 36.31 million CNY and a turnover rate of 1.17%. The total market capitalization is 6.365 billion CNY [1]. Fund Holdings - Morgan Stanley's fund holds a significant position in Bid Pharma, with the "Morgan Stanley Youyue Anhe Mixed A" fund (009893) owning 68,300 shares, representing 5.92% of the fund's net value, making it the second-largest holding. The estimated floating loss today is approximately 256,300 CNY [2]. Fund Performance - The "Morgan Stanley Youyue Anhe Mixed A" fund was established on September 24, 2020, with a current size of 28.9066 million CNY. Year-to-date, it has returned 22.41%, ranking 4046 out of 8172 in its category. Over the past year, it has returned 41.52%, ranking 4017 out of 7995. Since inception, it has incurred a loss of 27.95% [2]. Fund Management - The fund manager of "Morgan Stanley Youyue Anhe Mixed A" is Zhao Weijie, who has been in the position for 4 years and 205 days. The total asset size of the fund is 305 million CNY, with the best return during his tenure being 28.14% and the worst being -30% [3].

金价再创历史新高。 9月22日晚间，国际金价再度走高，期货、现货价格均刷新历史纪录。伦敦金现一度涨近1.2%，最高至3728.4美元/盎司；COMEX黄金一度涨超1.5%，最 高至3763.1美元/盎司。 上周，美联储宣布降息25个基点，并暗示在年底前会进一步降息。点阵图显示2025年降息中位数由6月的2次上调至3次，2026和2027年各一次，长期中性 利率维持在3%。截至目前，CME交易预期年内还有两次降息，于10月、12月分别降息25个基点的概率为91.9%、78.6%。 银河证券认为，本次美联储再次重启降息后，货币政策逐步宽松的趋势或已确立，后续在美国劳动力市场下滑的影响下美联储或将持续降息，推动全球黄金 ETF基金加速增持黄金来推升金价。 近日，摩根大通、瑞银等均上调了对金价的价格预测。 摩 根大通预计现货金价将在2025年第四季度达到3800美元/盎司，并在2026年第一季度突破4000 美元/盎司大关。瑞银预计，到2025年底金价将达到每盎司3800美元，高于此前预测的每盎司3500美元。到2026年中，金价可能在每盎司3900美元左右， 此前预测为每盎司3700美元。 不过，当地时间9月22日 ...

美股上周五继续造好，道指上升0.38%，标普500指数及纳指则分别上升0.49%及0.72%。反映中概股表 现之金龙指数则微跌0.25% 来源：市场资讯 （来源：真灼财经） 至于中港股市上周走势呈个别发展。A股方面，沪深两市全周表现反复，上综指累跌1.3%，不过深成指 则有较好表现，累升1.12%，并连续第二个星期上升。港股走势同样不俗，周中一度升至27,058点，再 创年内新高，虽然其后从高位回落，但全周计恒指仍升159点或0.6%，收报26,545点，科指表现则更 佳，升幅达到5.1%，收报6,294点。值得一提的是受富时罗素指数调整因素影响，上周五成交达到3,768 亿元。成份股中以百度(09888.HK)表现最佳，升幅超过14%，中芯(00981.HK)及美团(03690.HK)升幅同 样超过一成；汽车股表现亦佳，比亚迪(01211.HK)及理想汽车(02015.HK)分别上升8.6%及7.9%。至于表 现最差成份股分别是平保(02318.HK)、中海外(00688.HK)、阿里健康(00241.HK)及友邦(01299.HK)，股 价跌幅均超过5%。另外，上周多只股份出现异动，当中药捷安康(0261 ...

IPO Review and Registration Progress - Three companies were reviewed last week, with two IPO registrations approved and one company facing a delay in review [2][3] - Yuan Chuang Co., Ltd. and Xin Guang Yi both received approval for their IPOs, targeting the Shenzhen Main Board and the ChiNext Board respectively [2] - Yuan Chuang's main business involves the research, production, and sales of rubber tracks, with projected revenue of 1.349 billion yuan in 2024, an 18.19% increase year-on-year, but a 12.94% decline in net profit [2] - Xin Guang Yi focuses on high-performance special functional materials, with its performance closely tied to the FPC industry and consumer electronics [3] Upcoming IPOs - Four companies are scheduled for IPO reviews this week, including Bai Ao Sai Tu, Heng Dong Guang, Nan Wang Digital, and Mo Er Thread [4][5] - Bai Ao Sai Tu, a clinical pre-CRO and biotechnology firm, aims to raise 8 billion yuan, with projected revenues increasing from 534 million yuan in 2022 to 980 million yuan in 2024 [5] - Heng Dong Guang specializes in passive optical devices, reporting a 105.84% revenue increase to 1.021 billion yuan in the first half of 2025 [5] - Mo Er Thread, a GPU chip design company, plans to raise 8 billion yuan for various chip development projects, with a revenue of 702 million yuan in the first half of 2025 [6] New Stock Listings and Subscription Dynamics - One new stock, Shi Chang Co., Ltd., was listed last week, with a first-day increase of 271.56% [9] - Shi Chang specializes in automotive fuel systems, with a focus on lightweight and low-emission products, targeting major automotive manufacturers [10] - This week, You Sheng Co., Ltd. is set to be listed, focusing on lightweight components for new energy vehicles, reporting a 30.76% revenue growth in the first half of 2025 [11] - One new stock subscription is scheduled for Ao Mei Sen, with an issue price of 8.25 yuan per share, focusing on intelligent equipment manufacturing [12] New Applications and Approvals - Three new IPO applications were accepted last week at the Beijing Stock Exchange, including Jiu Mu Chemical, Bai Nuo Pharmaceutical, and Shen Lan Hua [7] - Jiu Mu Chemical, a subsidiary of Wanrun Co., focuses on OLED materials, reporting a revenue decline of 23.1% in the first half of 2025 [7] - Bai Nuo Pharmaceutical aims to raise 800 million yuan for drug development and digital platform projects, with a revenue of 287 million yuan in the first half of 2025 [8] - Shen Lan Hua, specializing in high-end organic pigments, reported a 25.04% revenue increase to 388 million yuan in the first half of 2025 [8]

Group 1 - Leading photovoltaic company GCL-Poly announced a strategic investment of approximately $700 million from international investment firm Wujin Capital, backed by a Middle Eastern sovereign fund [1] - Weimob Group also secured a $200 million subscription from Wujin Capital shortly after GCL-Poly's announcement, indicating a trend of international capital targeting Chinese industry leaders [1] - The participation of international capital in refinancing through methods like private placements and rights issues reflects a long-term investment perspective, emphasizing confidence in the fundamentals and growth potential of Chinese companies [1] Group 2 - The continuously optimized foreign investment policy environment in China supports international capital's participation in domestic company refinancing [2] - Recent policies, including the "Management Measures for Strategic Investment by Foreign Investors in Listed Companies," encourage long-term and value investments from foreign capital [2] - The State Administration of Foreign Exchange has issued guidelines to enhance the convenience of cross-border investment and financing, further facilitating foreign investment in China [2][3] Group 3 - The rapid development of China's technological innovation is reshaping international capital's perception of the Chinese economy, moving beyond the view of China as merely a "world factory" [4] - China's R&D investment is projected to exceed 3.6 trillion yuan in 2024, a 48% increase from 2020, with a research intensity surpassing the average of EU countries [4] - The number of high-tech enterprises in China has increased by 83% since 2020, indicating a robust growth in innovation capabilities [4] Group 4 - Significant achievements in various fields such as quantum technology and life sciences have positioned China as a global leader in innovation, with the country ranking 10th in comprehensive innovation capability by 2024 [4] - The pharmaceutical sector has seen substantial growth, with nearly $66 billion in licensing deals for innovative drugs in the first half of 2025, showcasing the potential for revenue generation [5] - In the humanoid robotics sector, over 83 projects have been disclosed in the first half of 2025, with contract amounts totaling nearly 330 million yuan, indicating a strong market demand and performance [5] Group 5 - International capital is transitioning from being mere financial investors to strategic partners, actively engaging in governance, technology collaboration, and market expansion for Chinese companies [5] - As China's capital market continues to open up, international capital is expected to increasingly invest in innovative technology firms, sharing in the growth and development benefits [5]

新华社北京9月21日电 题：约100种罕见病用药进医保！生命与希望在集结 新华社记者李恒、彭韵佳 这是一场关乎生命与希望的对话，一次科学与温情的交融。 9月20日至21日，2025年中国罕见病大会在京举行。大会传递的数据温暖且令人振奋：目前全国罕见病 诊疗协作网医院达419家，罕见病直报系统现有626家医院参加登记，罕见病目录扩展至207种病种，已 有约100种罕见病用药被纳入国家医保药品目录。 医者与患者、科研人员与药企代表……这不仅仅是一场探讨罕见病诊疗与关爱的会议，更如同一束光， 穿透"罕见"的迷雾，照亮一个国家正以制度之善、科技之新、人文之暖守护"罕见病群体"。 保障更全！多层次保障体系为患者点亮生命之光—— 最新数据显示，国家医保药品目录内罕见病用药覆盖42个罕见疾病种类。2024年医保基金为协议期内罕 见病药品支付86亿元，约占协议期药品总支付的7.7%。 "医保基金坚持'尽力而为、量力而行'，但罕见病用药保障不能仅靠基本医保。"国家医保局医药服务管 理司司长黄心宇说，我国正构建基本医保、大病保险、医疗救助三重保障体系，并积极探索商业健康保 险、社会慈善等多元保障路径。 从药物研发、快速审评、纳入 ...

Mergers and Acquisitions - Anhui Heli plans to acquire 51% stake in Jianghuai Heavy Industry [1] Share Buybacks and Equity Transfers - Gansu Guotou will receive 90% stake in Lanshi Group for free, becoming the indirect controlling shareholder [2] - Jian Sheng Group intends to repurchase shares worth between 150 million to 300 million RMB, with a maximum repurchase price of 14.69 RMB per share [3] - Goodway adjusts the maximum repurchase price from 53 RMB per share to 70 RMB per share [4] - Shareholder Lu Tichao plans to transfer 1.7 million shares, accounting for 2.0038% of the total share capital [5] - Zhengqiang shares' controlling shareholder will transfer 8.9% of shares [6] - Heyuan Gas plans to repurchase and cancel 45,000 restricted shares [7] External Investments and Daily Operations - Neusoft Group received a notification for a project involving a total amount of approximately 5.6 billion RMB for supplying intelligent cockpit domain controllers [8] - Fulian Precision's subsidiary received a 1.5 billion RMB advance payment from CATL to secure the supply of lithium iron phosphate [9] - Jian Sheng Group plans to invest 180 million RMB in a project to produce 60 million pairs of mid-to-high-end cotton socks and 30 million pieces of clothing in Vietnam [10] - Fengshan Group signed a technology development contract with Tsinghua University for the development of sodium-ion battery electrolytes and solid-state lithium-ion battery electrolytes [11] - Palm Holdings won a bid for a high-standard farmland construction project worth 433 million RMB [12] - Heng Rui Medicine's subsidiary received clinical trial approval for SHR-1139 injection [11] - Huaxiang plans to issue convertible bonds to raise no more than 1.308 billion RMB for core component capacity enhancement and industrial chain extension projects [12] - Shentong Express reported August express service revenue of 4.434 billion RMB, a year-on-year increase of 14.47%, with a business volume of 2.147 billion tickets, up 10.92% year-on-year [12] - YTO Express reported August express product revenue of 5.39 billion RMB, a year-on-year increase of 9.82%, with a business volume of 2.511 billion tickets, up 11.08% year-on-year [12]

Core Viewpoint - The theme of this year's World Patient Safety Day is "Safe Care for Every Newborn and Child," emphasizing the importance of patient-centered research in the medical industry [1] Group 1: Patient-Centric Approach - The company prioritizes patient needs by integrating safety and effectiveness into clinical research processes, asking critical questions about treatment efficacy and trial safety [2] - The company has completed over 1,500 clinical studies across more than 20 indications, including solid tumors and cardiovascular diseases, with a focus on critical phases II and III [2] - AI technology has facilitated the recruitment of patients for over 1,200 projects, making patient-centered services more accessible [2] Group 2: Safety Measures - The company has developed a "6S Safety Defense Line," which encompasses standards and a commitment to scientific rigor and respect for life throughout the research process [2] - Safety is prioritized from study design to risk management, data monitoring, and result output, ensuring it remains the foundational principle [2] Group 3: Focus on Pediatric Medication - An online event was held to discuss the "6S Safety Defense Line" in pediatric drug development, highlighting insights and practical experiences from industry experts [3] - The complexity and importance of pediatric drug development were emphasized, including regulatory requirements and research strategies [5] - Ethical standards must be followed in pediatric drug development to maximize benefits and minimize risks, with a focus on dosage selection and child-specific endpoints [6] Group 4: Pharmacovigilance - Special attention is required for safety risks in pediatric clinical trials, including unique adverse reactions and pharmacokinetic differences in children [7] - Innovative monitoring technologies and long-term safety tracking strategies are being developed to ensure the safety and efficacy of pediatric medications [7] Group 5: Future Commitment - The company is committed to patient safety year-round, aiming to integrate technological innovation with professional services to create comprehensive solutions that meet clinical needs [8] - The mission to safeguard lives and ensure patient safety remains a collective effort within the organization [8]

Core Viewpoint - The integration of advanced manufacturing and modern service industries is essential for accelerating the construction of a new development pattern in China, as highlighted by the release of the "Beijing Model" for industry integration at the 2025 Service Trade Fair [1][4]. Group 1: Integration Models - Xiaomi Group exemplifies a "software service + hardware manufacturing + ecological chain collaboration" model by creating platforms for supply chain information integration and collective procurement, enhancing the synergy between manufacturing and service sectors [1]. - China Railway Signal & Communication Corporation (CRSC) showcases an "intelligent manufacturing + testing and verification + engineering services" model, providing comprehensive lifecycle services for rail transit systems [1]. - Beijing Foton Motor Company demonstrates a "complete vehicle manufacturing + aftermarket services" model, extending its business from manufacturing to high-value-added aftermarket services through smart vehicle networking [2]. - Kanglong Chemical (300759) illustrates a "research and development + customized production" model, offering integrated drug development services across the entire process from discovery to clinical development [2]. - Baipusais (301080) employs a "testing + customized production" model, providing tailored production of pharmaceutical products based on advanced analysis methods [2]. - Xuedilong (002658) focuses on an "equipment R&D + manufacturing + system solutions" model, offering comprehensive solutions in environmental monitoring and carbon management [2]. Group 2: Advanced Technologies and Services - Shanshu Technology adopts an "artificial intelligence + (management, manufacturing) decision-making" model, applying decision science and optimization techniques to enhance production and operational efficiency [3]. - JD Logistics integrates "smart logistics + intelligent factories," collaborating with manufacturing firms to optimize supply chain management and reduce costs [3]. - BGI Electronics promotes a "chip R&D + manufacturing + services" model, fostering collaboration across the semiconductor industry to enhance domestic technology capabilities [3]. - Huajiang Culture introduces a "design + flexible customization + sales" model, creating a complete cultural product industry chain through innovative production lines [3]. Group 3: Policy and Future Directions - Beijing has identified eight key areas for the integration of industries and has established five national pilot enterprises and 67 municipal pilot enterprises to explore new integration models [4]. - The release of the "Beijing Model" is expected to serve as an effective demonstration, promoting deeper integration across various sectors and enhancing the overall ecosystem for industry integration [4].

Group 1: Hesai Group (禾赛) - Hesai Group plans to officially list in Hong Kong on September 16 with the stock code "2525", becoming the first global lidar company to list in Hong Kong [3] - The company has attracted six cornerstone investors, raising a total of $148 million (approximately HKD 1.15 billion), with notable contributions from existing shareholders [3] - In Q2, Hesai delivered a total of 352,095 lidar units, representing a year-on-year growth of 306.9%, with ADAS product deliveries at 303,564 units, up 275.8% [4] - For the first half of the year, total lidar deliveries reached 547,913 units, a 276.2% increase year-on-year, surpassing the full-year target for 2024 [4] - Hesai's revenue for Q2 was RMB 710 million, a growth of over 50% year-on-year, with a net profit exceeding RMB 40 million, significantly surpassing profitability targets [5] Group 2: Genfleet Therapeutics (劲方医药) - Genfleet Therapeutics plans to list in Hong Kong on September 19 under the stock code "2595.HK", with cornerstone investors committing a total of $100 million (approximately HKD 780 million) [7] - The company focuses on developing new treatment options for tumors, autoimmune, and inflammatory diseases, with eight candidate drugs in its pipeline, five of which are in clinical stages [7] - The core product GFH925 has shown a 49.1% objective response rate in key clinical trials and is set to be commercialized in collaboration with a partner [8] Group 3: Chery Automobile (奇瑞) - Chery has passed the Hong Kong Stock Exchange hearing and is recognized as the second-largest independent passenger car brand in China and the eleventh largest globally [10] - The company is projected to sell over 2.295 million vehicles globally in 2024, with a year-on-year growth exceeding 25% across various markets [10][11] - Financially, Chery's revenue is expected to grow from RMB 926.18 billion in 2022 to RMB 2,698.97 billion in 2024, with net profits increasing from RMB 58.06 billion to RMB 143.34 billion in the same period [12] Group 4: BeBeBus - BeBeBus, a high-end parenting product brand, has passed the Hong Kong Stock Exchange hearing and is set to list soon [14] - The company ranks first in the durable parenting products market for mid-to-high-end consumers in China, with a significant average transaction amount [14][15] - Financial performance shows revenue growth from RMB 5.07 billion in 2022 to RMB 12.49 billion in 2024, with a gross margin maintained above 49% [15][16]